

Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products




DEDICATED TO THE HEALTH OF ALL CHILDREN








12 years and older




a. For children who turn 4 to 5 years during their vaccine series, follow do sing recommendations based on age at the time of vaccination. For Pfizer vaccine, if the 10 mcg dose is the second dose, and the time of vaccination of the second dose, and the time of vaccination of the second dose, and the second dose, and the second dose, are the second dose, and the second dose, and the second dose, are the second dose, and the second dose, are the second dose, and the second dose, are the second dose, and the second dose, and the second dose, are the second dose, are the second dose, are the second dose, and the second dose, are the second dose, and the second dose, are the second dose, are the second dose, and the second dose, are the second dose, are the second dose, and the second dose, are the second dose, are the second dose, and the second dose, are the second dose, are the second dose, are the second dose, are the second dose, and the second dose, are the second dose, are the second dose, and the second dose, are theadminister 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose.

b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose, (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.

Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products for Individuals who are Moderately to Severely Immunocompromised




DEDICATED TO THE HEALTH OF ALL CHILDREN



- $\textbf{a.} For children \ who \ turn \ \textbf{4} \ \textbf{to} \ \textbf{5} \ years \ during \ their \ vaccine \ series, follow \ dosing \ recommendations \ based \ on \ age \ at \ the \ time \ of \ vaccination.$
- b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose, (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.
- c. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.
- d. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

Moderna COVID-19 Vaccine Products






 $[\]textbf{a.} For children \ who \ turn \ \textbf{4} \ \textbf{to} \ \textbf{5} \ \textbf{years} \ \textbf{during} \ \textbf{their} \ \textbf{vaccine} \ \textbf{series}, follow \ \textbf{dosing} \ \textbf{recommendations} \ \textbf{based} \ \textbf{on} \ \textbf{age} \ \textbf{at the time} \ \textbf{of vaccination}.$

b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose, (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.


c. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

 $[\]textbf{d.} For children who turn 11 to 12 years during their vaccine series, follow do sing recommendations based on age at the time of vaccination. The properties of the following their vaccinations of the properties of the following their vaccinations of the properties of the proper$

Pfizer-BioNTech COVID-19 Vaccine Products



DEDICATED TO THE HEALTH OF ALL CHILDRENS



a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination. For Pfizer vaccine, if the 10 mcg dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose.


b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose, (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.

c. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

d. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

Novavax COVID-19 Vaccine





12 years and older



